MedTrace Logo

Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

NCT03122132 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-05-21

No results posted yet for this study

Summary

The aim of the study is to evaluate in clinical practice the efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b hepatitis C virus (HCV).

Conditions

  • Hepatitis C Infection

Interventions

DRUG

ombitasvir/paritaprevir/ritonavir 8 weeks

Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks

DRUG

dasabuvir 8 weeks

Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks

Sponsors & Collaborators

  • Hepa C

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2018-01-01
Completion
2018-03-01
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03122132 on ClinicalTrials.gov